DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

As a result, the mechanisms underlying the impact of glucagon-like peptide-1 medications on the kidneys are unknown. Clinical trials and animal research support GLP-1 medication usage to treat ...

Glucagon-like peptide-1 (GLP-1) receptor agonists -- your patients are on them, and perhaps you are too (or at least have thought about it). In 2023, more than 500 million people worldwide were ...

The study found that a bimodal molecular strategy combining NMDA receptor antagonism and glucagon-like peptide-1 receptor antagonism could successfully correct obesity, hyperglycemia, and ...

With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only seen before through surgical intervention, obesity specialists say patients on these drugs are ...

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434-3438.

GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 diabetes and, in some cases, obesity. They work by mimicking the action of the hormone GLP-1, which helps regulate ...

DALLAS — Results presented at the American Association of Hip and Knee Surgeons Annual Meeting showed 14 days may be the optimal cutoff time for glucagon-like peptide-1 receptor agonists prior ...